CA2652999A1 - Methods, compositions, and kits for treating shiga toxin associated conditions - Google Patents

Methods, compositions, and kits for treating shiga toxin associated conditions Download PDF

Info

Publication number
CA2652999A1
CA2652999A1 CA002652999A CA2652999A CA2652999A1 CA 2652999 A1 CA2652999 A1 CA 2652999A1 CA 002652999 A CA002652999 A CA 002652999A CA 2652999 A CA2652999 A CA 2652999A CA 2652999 A1 CA2652999 A1 CA 2652999A1
Authority
CA
Canada
Prior art keywords
chimeric anti
day
antibodies
stx2
stec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002652999A
Other languages
English (en)
French (fr)
Inventor
Marc Riviere
Mariam Mehran
Claire Thunning Roberson
Alison O'brien
Angela Melton-Celsa
Janique Sam-Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thallion Pharmaceuticals Inc
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2652999A1 publication Critical patent/CA2652999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002652999A 2006-05-31 2007-05-31 Methods, compositions, and kits for treating shiga toxin associated conditions Abandoned CA2652999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80946406P 2006-05-31 2006-05-31
US60/809,464 2006-05-31
PCT/US2007/012797 WO2007143004A2 (en) 2006-05-31 2007-05-31 Methods, compositions, and kits for treating shiga toxin associated conditions

Publications (1)

Publication Number Publication Date
CA2652999A1 true CA2652999A1 (en) 2007-12-13

Family

ID=38802032

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002652999A Abandoned CA2652999A1 (en) 2006-05-31 2007-05-31 Methods, compositions, and kits for treating shiga toxin associated conditions

Country Status (6)

Country Link
US (1) US20120195891A1 (https=)
EP (2) EP2545936A3 (https=)
JP (1) JP2009538916A (https=)
AU (1) AU2007254950A1 (https=)
CA (1) CA2652999A1 (https=)
WO (1) WO2007143004A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US20130195851A1 (en) * 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
WO2006030883A1 (ja) * 2004-09-17 2006-03-23 Hamamatsu Foundation For Science And Technology Promotion モノクローナル抗体の製造方法
ES2532985T3 (es) * 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga

Also Published As

Publication number Publication date
EP2545936A2 (en) 2013-01-16
US20120195891A1 (en) 2012-08-02
EP2035037A4 (en) 2010-03-31
WO2007143004A2 (en) 2007-12-13
EP2035037A2 (en) 2009-03-18
AU2007254950A1 (en) 2007-12-13
JP2009538916A (ja) 2009-11-12
WO2007143004A3 (en) 2008-03-27
EP2545936A3 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
AU2016280555B2 (en) Anti-CGRP antibody formulation
US20120195891A1 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
JP6694269B2 (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
JP7823117B2 (ja) 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与
JP5954916B1 (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
WO2004062578A2 (en) Methods for reducing mortality associated with acute myocardial infarction
US20160168237A1 (en) Method for treating a complement mediated disorder caused by an infectious agent in a patient
US11732049B2 (en) Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor
EP2214709A1 (en) Use of angiogenesis antagonists in conditions of abnormal venous proliferation
CN112996561A (zh) 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
KR20190012199A (ko) 난치성 전신 중증 근무력증의 치료를 위한 방법
US20170081403A1 (en) Treatment of Diabetes
US20090258010A1 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
JP2002513398A (ja) フィブロネクチン結合タンパク質組成物および使用法
US20180085458A1 (en) Methods for treating clostridium difficile infection and associated disease
JP2023539047A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
EP4181922A1 (en) Methods of using factor b inhibitors
US20200172603A1 (en) Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
Bols et al. Recurrent meningococcal infections in a patient with congenital C5 deficiency
Scibona et al. A Phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab’) 2 fragments in healthy volunteers
Hai-Zhen et al. Rituximab successful in COVID-19 vaccine-induced refractory pemphigus vulgaris
Motley The Role of Anti-Capsular Antibodies in Protection Against Carbapenem-Resistant Klebsiella Pneumoniae
JP2026506954A (ja) Ｂ因子阻害剤を使用する方法
EA043233B1 (ru) ДОЗИРОВАНИЕ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИЕЙ (PNH) И АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (aHUS)
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140602